|Day Low/High||0.85 / 1.01|
|52 Wk Low/High||0.74 / 1.53|
ATLANTA, July 11, 2018 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that 8 presentations on ILUVIEN data have been accepted...
Ms. Szela brings extensive global brand experience to the Alimera Board
More patients in England and Wales with chronic DME could benefit from low-dose corticosteroid intravitreal implant that lasts up to three years
ATLANTA, June 4, 2018 /PRNewswire/ -- Alimera Sciences (NASDAQ: ALIM), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that it has terminated its October 2017 agreement for an investment bank...
Elimination of liquidity covenants frees working capital to fuel company growth
20 electronic posters available for review as well
Horus Pharma S.A.S. to also serve as agent in price negotiations with French Regulatory Authorities
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.